Acrivon Therapeutics Inc is a biotechnology company that is focused on the discovery and development of innovative therapies for cancer and other diseases. The company was founded in 2020 and is headquartered in San Diego, California. Acrivon's approach to drug discovery is based on the identification of new targets and the development of small molecule inhibitors to target those targets.
Acrivon's lead program is focused on the development of a small molecule inhibitor for the treatment of acute myeloid leukemia (AML). The company's preclinical data suggests that the inhibitor is effective in targeting AML cells and has the potential to be a breakthrough therapy for this deadly disease. Acrivon is also developing small molecule inhibitors for other oncology indications, including breast cancer and lung cancer.
With a team of experienced drug discovery and development experts, a strong focus on innovative science, and a commitment to improving patient outcomes, Acrivon is well-positioned to make significant advances in the field of oncology. The company is also committed to building strategic partnerships with leading academic institutions and pharmaceutical companies to accelerate the development and commercialization of its innovative therapies.